US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Emera Inc.

49.28

-0.1000-0.20%

Post-market: 49.280.00000.00%19:30 EDT

Volume:381.48K

Turnover:18.76M

Market Cap:15.07B

PE:22.10

High:49.32

Open:48.96

Low:48.66

Close:49.38

52wk High:55.49

52wk Low:45.78

Shares:305.78M

Float Shares:305.78M

Volume Ratio:1.45

T/O Rate:0.12%

Dividend:2.09

Dividend Rate:4.24%

EPS(TTM):2.23

EPS(LYR):2.47

ROE:7.56%

ROA:2.91%

PB:1.63

PE(LYR):19.99

Loading ...

Overview Company News Filings

INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB

Regeneron Gets FDA, EMA Review of Cemdisiran in Generalized Myasthenia Gravis

Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)

Hengrui Pharma's Novel Drug Application for Rezvilutamide Accepted by European Regulator

Top Three Reasons Why Tom Lee’s BMNR Stock May Be on the Cusp of a Deeper Dive

Benzinga_recent_news

WuXi Biologics (Cayman) (SEHK:2269) Stock Could Be 34.3% Undervalued After Clean EMA Inspection

Simply Wall St.

Cosmos Health Signs 2.86 Million-Unit Contract Manufacturing Agreement With Pharmex S.A. Across Three Dermatological Products

Zai Lab Receives EU Orphan Drug Designation for Lung Cancer Drug

MT Newswires Live

Press Release: GENFIT: June 15, 2026 Combined Shareholders Meeting Results

XRP Presents Strongest Move Since Dropping Below 50 EMA

GSK announces momelotinib granted ODD from U.S. FDA, EMA

Press Release: Cosmos Health Signs LOI to Acquire Doc Pharma S.A., a European GMP Pharmaceutical Manufacturer, a Transformative Step Expected to Boost Assets, Profitability, Production Capacity, and Product Portfolio

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial

Cosmos Health CEO Issues Letter to Shareholders: Building an Innovative AI-Driven Global Healthcare Platform — Record Growth with U.S. Expansion Underway

Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)

Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference

Cardano Price Hits All-Time Low: Why Charles Hoskinson's Project Failed

Cosmos Health Continues U.S. Expansion with Launch of Oliv18, Targeting Cardiovascular and Antioxidant Categories

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/EMA/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"EMA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","market":"US","secType":"STK","nameCN":"Emera Inc.","latestPrice":49.28,"timestamp":1789761600000,"preClose":49.38,"halted":0,"volume":381479,"hourTrading":{"tag":"盘后","latestPrice":49.28,"preClose":49.28,"latestTime":"19:30 EDT","volume":40384,"amount":1992699.06912,"timestamp":1789774206298,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0020251113811259906,"floatShares":305783111,"shares":305783111,"eps":2.229761,"marketStatus":"Market Closed","change":-0.1,"latestTime":"09-18 16:00:00 EDT","open":48.96,"high":49.32,"low":48.66,"amount":18759191.6771,"amplitude":0.013366,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.229761,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":7,"adr":0,"exchange":"NYSE","adjPreClose":49.38,"dividendRate":0.042791,"postHourTrading":{"tag":"盘后","latestPrice":49.28,"preClose":49.28,"latestTime":"19:30 EDT","volume":40384,"amount":1992699.06912,"timestamp":1789774206298,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.4540410074543813,"impliedVol":0.4231,"impliedVolPercentile":0.9761},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","floatShares":305783111,"roa":"2.91%","roe":"7.56%","lyrEps":2.465138,"volumeRatio":1.4540410074543813,"shares":305783111,"dividePrice":2.087723,"high":49.32,"amplitude":0.013366,"preClose":49.38,"low":48.66,"week52Low":45.78,"pbRate":"1.63","psRate":"2.36","week52High":55.49,"institutionHeld":0,"latestPrice":49.28,"eps":2.229761,"divideRate":0.042365,"volume":381479,"delay":0,"ttmEps":2.229761,"open":48.96,"prevYearClose":49.24,"prevWeekClose":49.19,"prevMonthClose":50.09,"prevQuarterClose":53.02,"fiveDayClose":49.19,"twentyDayClose":51.78,"sixtyDayClose":52.9,"dividendPayoutRate":0.8394110571990734,"dividendFrequency":"Q","dividendGrowthYears":0,"fiveYearAvgDividendRate":0.04206805783252231},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EMA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"EMA","fiscalQuarterEnding":"2026/06","expectedEps":0.51,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"pre","actualEps":0.5},{"date":"2026-08-03","symbol":"EMA","amount":0.7325,"announcedDate":"2026-07-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-03","defaultRemindTime":1785763800000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-03","currency":"CAD","dateTimestamp":1785729600000,"payDate":"2026-08-17"},{"market":"US","date":"2026-05-08","symbol":"EMA","fiscalQuarterEnding":"2026/03","expectedEps":0.89,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":1},{"date":"2026-05-01","symbol":"EMA","amount":0.7325,"announcedDate":"2026-04-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-01","defaultRemindTime":1777642200000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-15","payableDate":"2026-05-01","currency":"CAD","dateTimestamp":1777608000000,"payDate":"2026-05-15"},{"market":"US","date":"2026-02-23","symbol":"EMA","fiscalQuarterEnding":"2025/12","expectedEps":0.43,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1771822800000,"reportTimeType":"pre","actualEps":0.4}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EMA\",market:\"US\",,,undefined,":[{"executeDate":"2016-10-28","recordDate":"2016-11-01","paymentDate":"2016-11-15","value":0.3880294,"currency":"USD"},{"executeDate":"2025-08-01","recordDate":"2025-08-01","paymentDate":"2025-08-15","value":0.725,"currency":"CAD"},{"executeDate":"2025-10-31","recordDate":"2025-10-31","paymentDate":"2025-11-14","value":0.7325,"currency":"CAD"},{"executeDate":"2026-01-30","recordDate":"2026-01-30","paymentDate":"2026-02-13","value":0.7325,"currency":"CAD"},{"executeDate":"2026-05-01","recordDate":"2026-05-01","paymentDate":"2026-05-15","value":0.7325,"currency":"CAD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EMA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1778299200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EMA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EMA","date":"2026-09-18","current":22.101023,"percent":0.558282,"low":16.637027,"twenty":17.871551,"median":20.245144,"eighty":21.031403,"high":22.07626,"avg":19.830871,"sd":1.467509,"marketCap":15149228130.36},"quantilePoints":[{"date":"2025-05-30","current":19.76944,"twenty":19.76944,"median":19.76944,"eighty":19.76944,"marketCap":13505496352.43},{"date":"2025-06-06","current":19.324012,"twenty":19.535669,"median":19.692043,"eighty":19.76944,"marketCap":13350532994.37},{"date":"2025-06-13","current":19.308216,"twenty":19.137627,"median":19.324012,"eighty":19.722054,"marketCap":13371262392.6},{"date":"2025-06-20","current":19.245035,"twenty":19.160372,"median":19.387193,"eighty":19.674036,"marketCap":13211518175.96},{"date":"2025-06-27","current":19.308216,"twenty":19.224185,"median":19.382455,"eighty":19.560942,"marketCap":13348226238.04},{"date":"2025-07-03","current":19.469329,"twenty":19.242508,"median":19.399829,"eighty":19.679723,"marketCap":13533023992.92},{"date":"2025-07-11","current":19.753645,"twenty":19.282944,"median":19.43142,"eighty":19.706259,"marketCap":13611556279.78},{"date":"2025-07-18","current":19.592532,"twenty":19.308216,"median":19.502499,"eighty":19.712577,"marketCap":13439260670.95},{"date":"2025-07-25","current":20.116937,"twenty":19.317694,"median":19.614646,"eighty":19.767545,"marketCap":13920070443.21},{"date":"2025-08-01","current":20.552889,"twenty":19.356234,"median":19.663612,"eighty":19.931816,"marketCap":14004388886.88},{"date":"2025-08-08","current":20.884591,"twenty":19.383402,"median":19.706259,"eighty":20.124519,"marketCap":14315223696.17},{"date":"2025-08-15","current":20.686356,"twenty":19.389088,"median":19.714157,"eighty":20.375981,"marketCap":14241020029.57},{"date":"2025-08-22","current":21.111677,"twenty":19.401724,"median":19.753645,"eighty":20.511821,"marketCap":14434555399.62},{"date":"2025-08-29","current":20.468969,"twenty":19.420679,"median":19.785235,"eighty":20.581071,"marketCap":14130173597.74},{"date":"2025-09-05","current":20.484722,"twenty":19.429525,"median":19.883167,"eighty":20.585711,"marketCap":14060435241.25},{"date":"2025-09-12","current":20.283088,"twenty":19.441529,"median":20.015847,"eighty":20.549566,"marketCap":13928376571.28},{"date":"2025-09-19","current":19.923928,"twenty":19.461747,"median":20.073945,"eighty":20.542062,"marketCap":13714455884.59},{"date":"2025-09-26","current":20.585539,"twenty":19.495865,"median":20.087756,"eighty":20.542062,"marketCap":14040465233.16},{"date":"2025-10-03","current":21.108526,"twenty":19.558414,"median":20.183278,"eighty":20.617044,"marketCap":14341364686.36},{"date":"2025-10-10","current":21.127429,"twenty":19.601378,"median":20.281209,"eighty":20.758818,"marketCap":14318469638.17},{"date":"2025-10-17","current":21.666169,"twenty":19.623491,"median":20.300416,"eighty":20.797254,"marketCap":14653790731.95},{"date":"2025-10-24","current":21.757535,"twenty":19.646868,"median":20.374454,"eighty":20.916344,"marketCap":14770054950.94},{"date":"2025-10-31","current":21.360568,"twenty":19.663296,"median":20.386244,"eighty":21.06631,"marketCap":14513331426.12},{"date":"2025-11-07","current":21.272354,"twenty":19.674036,"median":20.41226,"eighty":21.097184,"marketCap":14296037747.86},{"date":"2025-11-14","current":17.374062,"twenty":19.601378,"median":20.386244,"eighty":21.06631,"marketCap":14568586353.81},{"date":"2025-11-21","current":17.212836,"twenty":19.441529,"median":20.374454,"eighty":21.041735,"marketCap":14368588864.66},{"date":"2025-11-28","current":17.407331,"twenty":19.394143,"median":20.301992,"eighty":21.030393,"marketCap":14577653448.13},{"date":"2025-12-05","current":16.921093,"twenty":19.311375,"median":20.282148,"eighty":21.003928,"marketCap":14257439118.84},{"date":"2025-12-12","current":16.693329,"twenty":19.18059,"median":20.230664,"eighty":20.983135,"marketCap":14234564864},{"date":"2025-12-19","current":17.167393,"twenty":17.900621,"median":20.102346,"eighty":20.957301,"marketCap":14657419004.37},{"date":"2025-12-26","current":17.216186,"twenty":17.458514,"median":20.073945,"eighty":20.944699,"marketCap":14789996894.17},{"date":"2026-01-02","current":17.370269,"twenty":17.373303,"median":20.0392,"eighty":20.932097,"marketCap":14871263471.89},{"date":"2026-01-09","current":17.43447,"twenty":17.368214,"median":19.923928,"eighty":20.903742,"marketCap":14773589152.84},{"date":"2026-01-16","current":17.439606,"twenty":17.353836,"median":19.83736,"eighty":20.887161,"marketCap":14748903694.51},{"date":"2026-01-23","current":17.57828,"twenty":17.358457,"median":19.76786,"eighty":20.862056,"marketCap":14967122519.73},{"date":"2026-01-30","current":17.452446,"twenty":17.36616,"median":19.731531,"eighty":20.822459,"marketCap":15149245081.41},{"date":"2026-02-06","current":17.639913,"twenty":17.358457,"median":19.706259,"eighty":20.792844,"marketCap":15150466223.22},{"date":"2026-02-13","current":17.632209,"twenty":17.329694,"median":19.687304,"eighty":20.780241,"marketCap":15197950382.19},{"date":"2026-02-20","current":18.01228,"twenty":17.336884,"median":19.662032,"eighty":20.776461,"marketCap":15461241242.05},{"date":"2026-02-27","current":19.370854,"twenty":17.349212,"median":19.603589,"eighty":20.77079,"marketCap":15419204876.87},{"date":"2026-03-06","current":19.860551,"twenty":17.357687,"median":19.614646,"eighty":20.758818,"marketCap":15772457447.89},{"date":"2026-03-13","current":20.172176,"twenty":17.364105,"median":19.663612,"eighty":20.731723,"marketCap":16126249798.12},{"date":"2026-03-20","current":19.982975,"twenty":17.371786,"median":19.706259,"eighty":20.697698,"marketCap":15868293252.05},{"date":"2026-03-27","current":19.866116,"twenty":17.374599,"median":19.676248,"eighty":20.661152,"marketCap":15623406729.11},{"date":"2026-04-02","current":20.186088,"twenty":17.375919,"median":19.706259,"eighty":20.620195,"marketCap":15797694590.77},{"date":"2026-04-10","current":20.433719,"twenty":17.383333,"median":19.710303,"eighty":20.603182,"marketCap":16095943521.79},{"date":"2026-04-17","current":20.225489,"twenty":17.405284,"median":19.739002,"eighty":20.583555,"marketCap":16062393790.34},{"date":"2026-04-24","current":20.11598,"twenty":17.412759,"median":19.756565,"eighty":20.571074,"marketCap":16011506016.84},{"date":"2026-05-01","current":20.349038,"twenty":17.435497,"median":19.769087,"eighty":20.551228,"marketCap":16279588937.86},{"date":"2026-05-08","current":20.003663,"twenty":17.442174,"median":19.801031,"eighty":20.543322,"marketCap":15972071463.03},{"date":"2026-05-15","current":20.526748,"twenty":17.453473,"median":19.863334,"eighty":20.551228,"marketCap":15993082457.11},{"date":"2026-05-22","current":20.821212,"twenty":17.457768,"median":19.873689,"eighty":20.574777,"marketCap":16159791825.34},{"date":"2026-05-29","current":20.784047,"twenty":17.458514,"median":19.874498,"eighty":20.606796,"marketCap":16109213261.77},{"date":"2026-06-05","current":20.455276,"twenty":17.46015,"median":19.931505,"eighty":20.606796,"marketCap":15744335184.44},{"date":"2026-06-12","current":20.798341,"twenty":17.481546,"median":19.990575,"eighty":20.612514,"marketCap":15890994194.64},{"date":"2026-06-18","current":20.901261,"twenty":17.493192,"median":20.015847,"eighty":20.650154,"marketCap":15823421326.33},{"date":"2026-06-26","current":21.595968,"twenty":17.496103,"median":20.061717,"eighty":20.767009,"marketCap":16281617755.86},{"date":"2026-07-02","current":21.507343,"twenty":17.504259,"median":20.064683,"eighty":20.784032,"marketCap":16222688501.02},{"date":"2026-07-10","current":21.544508,"twenty":17.526194,"median":20.082188,"eighty":20.821212,"marketCap":16271827884.13},{"date":"2026-07-17","current":21.936175,"twenty":17.541814,"median":20.087829,"eighty":20.898969,"marketCap":16718811747.19},{"date":"2026-07-24","current":22.07626,"twenty":17.564926,"median":20.116937,"eighty":20.951,"marketCap":16761941188.16},{"date":"2026-07-31","current":21.66744,"twenty":17.586675,"median":20.124404,"eighty":21.004011,"marketCap":16545696607.24},{"date":"2026-08-07","current":20.666833,"twenty":17.604226,"median":20.156816,"eighty":21.026741,"marketCap":15758445214.07},{"date":"2026-08-14","current":21.122954,"twenty":17.619883,"median":20.180562,"eighty":21.040346,"marketCap":15758083883.88},{"date":"2026-08-21","current":21.131815,"twenty":17.635291,"median":20.20188,"eighty":21.05159,"marketCap":15955602988.26},{"date":"2026-08-28","current":20.499692,"twenty":17.645049,"median":20.225489,"eighty":21.044992,"marketCap":15379168560.24},{"date":"2026-09-04","current":20.473108,"twenty":17.659944,"median":20.257815,"eighty":21.043803,"marketCap":15442660903.12},{"date":"2026-09-11","current":20.227938,"twenty":17.708223,"median":20.275847,"eighty":21.041773,"marketCap":15223834714.33},{"date":"2026-09-18","current":20.381538,"twenty":17.871551,"median":20.245144,"eighty":21.031403,"marketCap":15149228130.36}],"updateTime":1789890973722},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EMA\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2645836813","title":"INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB","url":"https://stock-news.laohu8.com/highlight/detail?id=2645836813","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645836813?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:00","pubTimestamp":1782216000,"startTime":"0","endTime":"0","summary":"MHRA minutes from May 12 pre-MAA Scientific Advice meeting confirm agreement across all questions covering CMC, non-clinical and clinical evidence packagesMHRA pediatric feedback recognizes MissionEB ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/23/3315912/0/en/INmune-Bio-Receives-MHRA-Written-Alignment-Supporting-Planned-2026-UK-Conditional-Marketing-Authorization-Application-for-CORDStrom-in-RDEB.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","PIP","BK4139","MAA","BK4215","BK4585","INMB","BK4588","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645141021","title":"Regeneron Gets FDA, EMA Review of Cemdisiran in Generalized Myasthenia Gravis","url":"https://stock-news.laohu8.com/highlight/detail?id=2645141021","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645141021?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:33","pubTimestamp":1782127980,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals said U.S. and European regulators have accepted its applications seeking approval of its cemdisiran drug candidate in the rare and chronic autoimmune disease generalized myasthenia gravis, or gMG.Regeneron on Monday said the U.S. Food and Drug Administration and the European Medicines Agency will review cemdisiran to for adults with gMG who are anti-acetylcholine receptor antibody-positive.The Tarrytown, N.Y., biotechnology company said the FDA has granted the application priority review, which shortens the review period, and that it set a target action date in November.Regeneron, which is developing cemdisiran under a licensing agreement with Alnylam Pharmaceuticals, said it expects a decision from the European Commission in the second half of 2027.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","BK4588","EMA","LU2089984988.USD","LU2237438978.USD","LU0289739699.SGD","LU0823434583.USD","REGN","BK4548","LU2362540622.SGD","LU0109394709.USD","BK4585","LU0320765992.SGD","LU2468319806.SGD","LU2362541273.HKD","LU0882574055.USD","LU1974910355.USD","LU0889565916.HKD","BK4139","LABU","LU2362541513.USD","LU0823434740.USD","ALNY","LU0114720955.EUR","LU0053666078.USD","LU0823416689.USD","LU1917777945.USD","LU2106854487.HKD","LU0058720904.USD","LU2023250504.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645021109","title":"Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645021109","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645021109?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:00","pubTimestamp":1782126000,"startTime":"0","endTime":"0","summary":"Cemdisiran could be the first siRNA approved for the treatment of gMG and only therapy to be offered subcutaneously with four times a year dosing FDA accepted NDA under Priority Review with a target a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/22/3315167/0/en/Cemdisiran-Regulatory-Submissions-Accepted-for-Review-by-FDA-and-EMA-for-the-Treatment-of-Generalized-Myasthenia-Gravis-gMG.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","BK4139","LU2362541273.HKD","LU0823416689.USD","LU0823434740.USD","LU2362541513.USD","LU2362540622.SGD","BK4588","BK4585","BK4081","LU0823434583.USD","REGN","LU0109394709.USD","LU1974910355.USD","LU2468319806.SGD","LU0882574055.USD","LU1917777945.USD","LU2237438978.USD","LABU","LU0114720955.EUR","LU2089984988.USD","LU2106854487.HKD","LU2023250504.SGD","LU0889565916.HKD","LU0053666078.USD","LU0320765992.SGD","LU0289739699.SGD","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191996353","title":"Hengrui Pharma's Novel Drug Application for Rezvilutamide Accepted by European Regulator","url":"https://stock-news.laohu8.com/highlight/detail?id=1191996353","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191996353?lang=en_us&edition=fundamental","pubTime":"2026-06-22 16:48","pubTimestamp":1782118137,"startTime":"0","endTime":"0","summary":"An application for marketing authorization of a new drug developed by Jiangsu Hengrui Pharmaceuticals Co.,Ltd. (ASX: 600276) has been formally accepted for review by the European Medicines Agency...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","LU1997244956.HKD","LU1997245177.USD","LU1328615791.USD","LU2097828474.EUR","BK1191","LU2097828714.EUR","LU2148510915.USD","LU1997245094.SGD","LU1023057109.AUD","LU2543165471.USD","LU2488822045.USD","LU2289578879.USD","IPOS","EMA","LU2328871848.SGD","LU1969619763.USD","BK0028","LU2097828557.USD","BK0196","LU2097828805.USD","LU2495084118.USD","BK0012","LU1580142542.USD","01276","LU2580892862.HKD","LU1064131003.USD","LU0359202008.SGD","LU2580892789.USD","LU0359201885.HKD","LU0405327494.USD","LU0359201612.USD","BK4081","LU1146622755.USD","BK0183","BK0060","LU1064130708.USD","LU2097828631.EUR","LU1255011170.USD","LU1655091616.SGD","BK0239","600276","LU1820825898.SGD","LU1781817850.SGD","LU0405327148.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645504310","title":"Top Three Reasons Why Tom Lee’s BMNR Stock May Be on the Cusp of a Deeper Dive","url":"https://stock-news.laohu8.com/highlight/detail?id=2645504310","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645504310?lang=en_us&edition=fundamental","pubTime":"2026-06-22 05:26","pubTimestamp":1782077160,"startTime":"0","endTime":"0","summary":"Tom Lee's BMNR stock price has dropped sharply in the past 12 months, and this trend may continue in the foreseeable future as risks rise.","market":"sh","thumbnail":"https://cdn.benzinga.com/cdn-cgi/image/width=240,format=auto,quality=85/files/images/story/2026/06/21/tom-lee-dall-e.png","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/cdn-cgi/image/width=240,format=auto,quality=85/files/images/story/2026/06/21/tom-lee-dall-e.png"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/tech/26/06/60005784/top-three-reasons-why-tom-lees-bmnr-stock-may-be-on-the-cusp-of-a-deeper-dive","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/tech/26/06/60005784/top-three-reasons-why-tom-lees-bmnr-stock-may-be-on-the-cusp-of-a-deeper-dive","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["09046","03179","EETH","ETH.USD.CC","ETHD","ARKY","BMNG","ETH.USD.HKCC","GDLC","YETH","CETH","EZET","AETH","ETHW","ETQ","09009","09179","CRPT","LFGY","03046","03009","BETH","STCE","BETE","BMNZ","YBMN","ETHU","ETHV","BCCC","BFJL","BITQ","ETH","ETU","FETH","QETH","EMA","QBF","BMNU","BKCH","ETCO","BTF","BMNR","ETHI","BITW","SETH","ETHT","BITB","ETHA","BEGS","ETHE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644985740","title":"WuXi Biologics (Cayman) (SEHK:2269) Stock Could Be 34.3% Undervalued After Clean EMA Inspection","url":"https://stock-news.laohu8.com/highlight/detail?id=2644985740","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644985740?lang=en_us&edition=fundamental","pubTime":"2026-06-20 19:31","pubTimestamp":1781955097,"startTime":"0","endTime":"0","summary":"Why the EMA inspection matters for WuXi Biologics (Cayman)\nThe latest move in WuXi Biologics (Cayman) (SEHK:2269) stock comes after its Suzhou Biosafety Testing Center passed a four day European Medicines Agency GMP inspection with zero critical findings, backing 19 EU biologics applications.\nFor investors, this clean outcome highlights that a key part of WuXi Biologics (Cayman)'s testing and quality control operations aligns with European regulatory expectations, which can be important when...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/wuxi-biologics-cayman-sehk2269-stock-could-be-343-undervalue","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/wuxi-biologics-cayman-sehk2269-stock-could-be-343-undervalue","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1589","LU0052750758.USD","LU0456846285.SGD","LU0043850808.USD","LU0140636845.USD","SG9999002463.SGD","BK1576","LU0516423174.USD","LU1794554557.SGD","LU1720050803.USD","LU0359201612.USD","LU0708995583.HKD","LU0417516902.SGD","LU0051755006.USD","SG9999002562.SGD","LU1242518857.USD","LU0327786744.USD","LU0417516738.SGD","LU0516423091.SGD","EMA","02269","LU0819121731.USD","BK1141","IE00B0JY6N72.USD","LU0572944931.SGD","LU0516422952.EUR","LU0359202008.SGD","BK4081","LU0588546209.SGD","BK1521","LU0823426308.USD","LU0181495838.USD","LU0516422440.USD","LU0979878070.USD","LU0320764599.SGD","LU0348825331.USD","LU3063872942.SGD","LU0856984785.SGD","LU0823426480.USD","LU0039217434.USD","BK1610","LU0326950275.SGD","LU1242518931.SGD","LU0307460666.USD","LU1688375341.USD","LU0456827905.SGD","LU2039709279.SGD","LU1880383366.USD","LU0348735423.USD","LU0516422366.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644414037","title":"Cosmos Health Signs 2.86 Million-Unit Contract Manufacturing Agreement With Pharmex S.A. Across Three Dermatological Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2644414037","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644414037?lang=en_us&edition=fundamental","pubTime":"2026-06-17 21:27","pubTimestamp":1781702820,"startTime":"0","endTime":"0","summary":"CHICAGO, June  17, 2026  (GLOBE NEWSWIRE) -- Cosmos Health Inc. (\"Cosmos Health\" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that, th","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/17/3313521/0/en/Cosmos-Health-Signs-2-86-Million-Unit-Contract-Manufacturing-Agreement-With-Pharmex-S-A-Across-Three-Dermatological-Products.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4175","EMA","COSM","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643510567","title":"Zai Lab Receives EU Orphan Drug Designation for Lung Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2643510567","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643510567?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:34","pubTimestamp":1781609689,"startTime":"0","endTime":"0","summary":"Zai Lab  said Tuesday that the European Medicines Agency  has granted orphan drug designation to its experimental therapy, zocilurtatug pelitecan, for the treatment of pulmonary neuroendocrine carcinomas, a type of lung cancer.The company said the designation follows a recommendation from the EMA's Committee for Orphan Medicinal Products, which cited preliminary clinical data suggesting that the therapy may offer a clinically meaningful advantage over currently approved treatments for relapsed or refractory extensive-stage small cell lung cancer, including the potential for durable responses.Zai Lab said the orphan designation provides regulatory incentives that may support the therapy's development, including potential market exclusivity upon approval, reduced regulatory fees, and enhanced regulatory support.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4156","LU2488822045.USD","ZLAB","BK4588","EMA","EMA.AU","BK4531","BK4585","BK4139","BK7129","BK4081","BK4526","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643202739","title":"Press Release: GENFIT: June 15, 2026 Combined Shareholders Meeting Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2643202739","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643202739?lang=en_us&edition=fundamental","pubTime":"2026-06-16 00:10","pubTimestamp":1781539800,"startTime":"0","endTime":"0","summary":"-- All resolutions recommended by the Board of Directors approved (quorum:. Lille ; Cambridge, ; Zurich ; June 15, 2026 - GENFIT ,, a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the results of the Combined Shareholders Meeting which took place on June 15, 2026. The quorum on first convening amounted to 32.13 % and shareholders approved all of the resolutions, with the exception of resolution ndeg26 which was rejected in accordance with the recommendations of the Board of Directors.The voting results, resolution by resolution, are available in the Investors & Media section of the Company's website .This press release contains certain forward-looking statements with respect to GENFIT. The use of certain words, such as \"believe\", \"potential\", \"expect\", \"target\", \"may\", \"will\", \"should\", \"could\", \"if\"","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4604","USA","TM","03160","BK4232","EMA","BK4022","BK4555","CCA","HE","R","AD","BK4588","BK4081","BK4132","PBC","BK4099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643207889","title":"XRP Presents Strongest Move Since Dropping Below 50 EMA","url":"https://stock-news.laohu8.com/highlight/detail?id=2643207889","media":"utoday","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643207889?lang=en_us&edition=fundamental","pubTime":"2026-06-15 10:33","pubTimestamp":1781490780,"startTime":"0","endTime":"0","summary":"After weeks of intense selling pressure, XRP is finally beginning to show signs of life.The asset experienced a severe correction that drove it toward the $1.10 region after breaking below the 50-day ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"utodaynews_highlight","url":"https://u.today/xrp-presents-strongest-move-since-dropping-below-50-ema","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://u.today/xrp-presents-strongest-move-since-dropping-below-50-ema","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"utodaynews_highlight","symbols":["XXRP","XRP","XRPC","BK7129","XRPI","XRPK","EMA","XRPR","EMA.AU","XRPT","BITW","XRPZ","TOXR","UXRP","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642267278","title":"GSK announces momelotinib granted ODD from U.S. FDA, EMA","url":"https://stock-news.laohu8.com/highlight/detail?id=2642267278","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642267278?lang=en_us&edition=fundamental","pubTime":"2026-06-12 19:07","pubTimestamp":1781262453,"startTime":"0","endTime":"0","summary":"GSK (GSK) announced that momelotinib, a JAK inhibitor with a differentiated mechanism of action, has received Orphan Drug Designation, ODD, from th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gsk-announces-momelotinib-granted-odd-from-u-s-fda-ema-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gsk-announces-momelotinib-granted-odd-from-u-s-fda-ema-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EMA","GSK.UK","GSKH","BK4183","IE0009354923.USD","BK4588","GSK","BK4007","LABU","ODD","BK4081","BK4585","BK4532","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642023976","title":"Press Release: Cosmos Health Signs LOI to Acquire Doc Pharma S.A., a European GMP Pharmaceutical Manufacturer, a Transformative Step Expected to Boost Assets, Profitability, Production Capacity, and Product Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2642023976","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642023976?lang=en_us&edition=fundamental","pubTime":"2026-06-12 03:31","pubTimestamp":1781206260,"startTime":"0","endTime":"0","summary":"-- Doc Pharma financial profile: approximately $24 million asset base,approximately $6.7 million in average annual revenue and approximately. -- Immediately accretive: expected to support margin expansion,-- Deepens vertical integration: expected to drive synergies, optimized. production, economies of scale, expanded capacity, and a strengthened R&D. square feet, built to the highest European standards, providing a clear. -- Manufacturing excellence: a broad range of dosage forms, certified to GMP,ISO, Kosher, and Halal standards, with site registrations for the UAE,-- Boosts product portfolio: adds advanced and branded generics and OTC. CHICAGO, June 11, 2026  -- Cosmos Health Inc.  , a diversified, vertically integrated global healthcare group, today announced that it has entered into a non-binding letter of intent  to acquire 100% of Doc Pharma S.A. , a fully licensed GMP pharmaceutical manufacturer.Doc Pharma operates an approximately 59,000-square-foot, GMP-licensed production fac","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COSM","BK4232","EMA","BK4175","BK4081","EPV","BK4022","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642402214","title":"Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2642402214","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642402214?lang=en_us&edition=fundamental","pubTime":"2026-06-11 16:00","pubTimestamp":1781164800,"startTime":"0","endTime":"0","summary":"ZUG, Switzerland, June  11, 2026  (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/11/3310224/0/en/Oculis-to-Present-Privosegtor-at-Upcoming-Clinical-Trials-at-the-Summit-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0210528500.USD","LU0106261372.USD","LU0912757837.SGD","LU1861220033.SGD","LU1989772923.USD","LU0528227936.USD","LU2487616109.SGD","LU1861219969.SGD","ON","BK4585","LU1720051017.SGD","SMMF","BK4534","LU1978683503.SGD","BK4211","LU0390134368.USD","LU0314104364.USD","BK4516","LU2357305700.SGD","LU1732799900.SGD","LU2133065610.SGD","BK4605","LU0267386448.USD","LU2023251221.USD","EMA","LU2089284900.SGD","OCS","LU1363072403.SGD","LU0348723411.USD","BK4581","LU0795875169.SGD","LU1668664300.SGD","LU1861214812.USD","LU2028103732.USD","LU2111349929.HKD","LU1064131342.USD","LU1244550221.USD","LU0795875086.SGD","BK4081","LU0106831901.USD","LU2360107325.USD","LU0320765646.SGD","LU0006306889.USD","LU1244550577.SGD","LU1791710582.SGD","LU0225283273.USD","LU1854103824.USD","LU0724618433.USD","LU2271345857.HKD","LU1989772840.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642022134","title":"Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2642022134","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642022134?lang=en_us&edition=fundamental","pubTime":"2026-06-11 16:00","pubTimestamp":1781164800,"startTime":"0","endTime":"0","summary":"ZUG, Switzerland, June 11, 2026 – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/11/3310226/0/en/Oculis-to-Present-Privosegtor-at-Upcoming-Clinical-Trials-at-the-Summit-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0912757837.SGD","LU1989772923.USD","LU1861215975.USD","LU1861219969.SGD","ON","IE00BFMHRM44.USD","BK4585","BK4007","LU0053666078.USD","LU1988902786.USD","SMMF","BK4534","LU1978683503.SGD","LU2264538146.SGD","LU0390134368.USD","LU0158827781.USD","LU0314104364.USD","LU2357305700.SGD","LU1732799900.SGD","LU2133065610.SGD","LU2089283258.USD","BK4605","LU1854104046.USD","LU0267386448.USD","EMA","IE00BD6J9T35.USD","OCS","LU1162221912.USD","LU1363072403.SGD","LU0348723411.USD","LU1668664300.SGD","LU1732800096.USD","LU0557290698.USD","LU2028103732.USD","LU2111349929.HKD","LU1791710400.SGD","LU1548497426.USD","LU2360107325.USD","BK4127","LU0006306889.USD","LU0971096721.USD","IE00BKVL7J92.USD","LU1244550577.SGD","LU1791710582.SGD","LU1854103824.USD","LU2298322129.HKD","LU0724618433.USD","LU2271345857.HKD","LU0882574139.USD","LU1989772840.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642209429","title":"MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2642209429","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642209429?lang=en_us&edition=fundamental","pubTime":"2026-06-10 21:15","pubTimestamp":1781097300,"startTime":"0","endTime":"0","summary":"Additional data from MAIA’s THIO-101 expansion may further support an accelerated approval filing with the FDA Potential breakthrough therapy holds substantial commercial opportunity in a projected $7","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/10/3309785/0/en/MAIA-Biotechnology-Activates-and-Opens-Enrollment-at-Second-U-S-Clinical-Site-for-International-Phase-2-THIO-101-Expansion-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2487616109.SGD","BK4588","LU0210528500.USD","BK4139","LU0053666078.USD","MAIA","L","EMA","ORR","CPI","BK4107","BK4585","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642293144","title":"Cosmos Health CEO Issues Letter to Shareholders: Building an Innovative AI-Driven Global Healthcare Platform — Record Growth with U.S. Expansion Underway","url":"https://stock-news.laohu8.com/highlight/detail?id=2642293144","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642293144?lang=en_us&edition=fundamental","pubTime":"2026-06-10 21:00","pubTimestamp":1781096400,"startTime":"0","endTime":"0","summary":"Key Highlights Record revenue, continued momentum: all-time high $65.3M in FY2025; strongest-ever Q1 2026, carrying into Q2.Record operational momentum: CosmoFarm wholesale distribution and GMP-certif","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/10/3309738/0/en/Cosmos-Health-CEO-Issues-Letter-to-Shareholders-Building-an-Innovative-AI-Driven-Global-Healthcare-Platform-Record-Growth-with-U-S-Expansion-Underway.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK4175","BK4585","AGIX","COSM","LABU","XLV","ARTY","BK4581","LU0029874061.USD","BK4137","LU0128526141.USD","XBI","BK4588","CHAT","AIPO","HCSG","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642498269","title":"Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642498269","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642498269?lang=en_us&edition=fundamental","pubTime":"2026-06-09 21:20","pubTimestamp":1781011200,"startTime":"0","endTime":"0","summary":"MIAMI, June  09, 2026  (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-rel","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/09/3308957/0/en/Longeveron-Granted-Small-or-Medium-sized-Enterprise-SME-Status-by-the-European-Medicines-Agency-EMA.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN","EMA","EPV","MSC","BK4081","BK4139","BK4575","BK4150","MDCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642436001","title":"Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2642436001","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642436001?lang=en_us&edition=fundamental","pubTime":"2026-06-09 02:45","pubTimestamp":1780944300,"startTime":"0","endTime":"0","summary":"Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophthalmic diseases with significant u","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/08/3308406/0/en/Oculis-to-Present-at-the-47th-Annual-Goldman-Sachs-Global-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443382.USD","LU0128526141.USD","IE00BD6J9T35.USD","LU0348723411.USD","LU2471134879.HKD","BK4585","IE0004086264.USD","EMA","LU1804176565.USD","LU2237443549.SGD","LU1861219969.SGD","LU1861220033.SGD","LU0048573561.USD","BK4581","LU0345770993.USD","XLV","LU2237443465.HKD","LABU","LU0029874061.USD","ON","BK4137","LU1868836591.USD","LU1854103824.USD","LU1668664300.SGD","LU2471134523.USD","LU2357305700.SGD","IE00BFXG1179.USD","XBI","BK4550","LU2750360997.AUD","IE0034235188.USD","LU1978683503.SGD","BK4552","LU1868836757.USD","LU0096364046.USD","GSX","OCS","HCSG","LU0345770308.USD","BK4141","LU0106831901.USD","LU1720051017.SGD","LU1791807156.HKD","LU1868837300.USD","LU1861214812.USD","LU2237443978.SGD","IE00BSNM7G36.USD","LU1868837136.USD","LU0868494708.USD","IE0004091025.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641063124","title":"Cardano Price Hits All-Time Low: Why Charles Hoskinson's Project Failed","url":"https://stock-news.laohu8.com/highlight/detail?id=2641063124","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641063124?lang=en_us&edition=fundamental","pubTime":"2026-06-06 23:47","pubTimestamp":1780760863,"startTime":"0","endTime":"0","summary":"Cardano (CRYPTO: ADA) price retreated for the fourth consecutive weeks and reached a record low, continuing a downward spiral that started in September 2021 when it pe","market":"nz","thumbnail":"https://www.benzinga.com/files/images/story/2026/06/06/Cardano-Cryptocurrencies-And-Graph-Stati.jpeg","type":0,"news_type":0,"thumbnails":["https://www.benzinga.com/files/images/story/2026/06/06/Cardano-Cryptocurrencies-And-Graph-Stati.jpeg"],"rights":{"source":"Benzinga","url":"https://www.benzinga.com/crypto/cryptocurrency/26/06/53047638/cardano-price-hits-all-time-low-why-charles-hoskinsons-project-failed","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/crypto/cryptocurrency/26/06/53047638/cardano-price-hits-all-time-low-why-charles-hoskinsons-project-failed","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"Benzinga","symbols":["BK4081","EMA","BKCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641437911","title":"Cosmos Health Continues U.S. Expansion with Launch of Oliv18, Targeting Cardiovascular and Antioxidant Categories","url":"https://stock-news.laohu8.com/highlight/detail?id=2641437911","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641437911?lang=en_us&edition=fundamental","pubTime":"2026-06-05 21:25","pubTimestamp":1780665900,"startTime":"0","endTime":"0","summary":"Science-backed, USDA and EU-certified, whole olive tree supplement for two major wellness categories — rapidly growing global market projected to exceed $33 billionOliv18 expands the 18 Series with a ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/05/3307433/0/en/Cosmos-Health-Continues-U-S-Expansion-with-Launch-of-Oliv18-Targeting-Cardiovascular-and-Antioxidant-Categories.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","BK4082","CSII","COSM","BK4232","PAL","BK4175","EMA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":200,"code":"91000000","status":"200"}]}}